2023-11-10 15:01:00
A Federal Drug Administration (FDA), a United States body equivalent to Anvisa in Brazil, approved last Thursday (9) the first single-dose vaccine once morest chikungunya. Ixchiq is indicated for people aged 18 or over who are at increased risk of exposure to the virus that causes the disease and is transmitted through the bite of an infected mosquito.
The vaccine uses attenuated virus technology, a weakened version capable of inducing the human immune system to produce antibodies once morest the infectious agent. This disease is passed through Temples of the Egyptianswhich is also the cause of dengue, being especially serious in pregnant women and minors.
Chikungunya is an emerging global health threat, with at least 5 million cases of chikungunya virus infection reported over the past 15 years. The greatest risk of infection is in the tropical and subtropical regions of Africa, Southeast Asia and parts of the Americas, where mosquitoes carrying the chikungunya virus are endemic.
“Chikungunya virus infection can lead to serious illness and long-term health problems, especially for older adults and people with underlying medical conditions,” said Peter Marks, M.D., Ph.D., director of the Center for Evaluation and Research in Biological Products from the FDA.
The list of possible adverse reactions includes:
Headache; Fatigue; Muscle aches; Joint pain; Fever; Nausea; Tenderness at the injection site.
1699650490
#United #States #health #authority #approves #singledose #vaccine #chikungunya
